Grandeur Peak Global Advisors LLC Takes Position in DexCom, Inc. $DXCM

Grandeur Peak Global Advisors LLC purchased a new position in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 46,068 shares of the medical device company’s stock, valued at approximately $3,103,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of DXCM. MassMutual Private Wealth & Trust FSB raised its holdings in DexCom by 15.4% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock valued at $77,000 after acquiring an additional 153 shares during the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after purchasing an additional 172 shares during the last quarter. Essex Financial Services Inc. boosted its holdings in shares of DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock worth $204,000 after purchasing an additional 175 shares during the last quarter. Keel Point LLC grew its position in shares of DexCom by 3.1% in the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock valued at $430,000 after purchasing an additional 193 shares in the last quarter. Finally, Integrated Wealth Concepts LLC grew its position in shares of DexCom by 6.3% in the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock valued at $227,000 after purchasing an additional 196 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the transaction, the executive vice president owned 106,353 shares of the company’s stock, valued at $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the sale, the director owned 52,852 shares of the company’s stock, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 73,035 shares of company stock worth $5,446,673. 0.28% of the stock is owned by corporate insiders.

DexCom Price Performance

NASDAQ:DXCM opened at $89.29 on Friday. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $92.59. The stock’s fifty day moving average is $78.84 and its two-hundred day moving average is $71.47. The company has a market capitalization of $33.69 billion, a P/E ratio of 35.29, a P/E/G ratio of 1.50 and a beta of 1.41. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company’s revenue was up 13.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.48 EPS. Equities analysts expect that DexCom, Inc. will post 2.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Sanford C. Bernstein set a $77.00 price objective on DexCom in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft assumed coverage on DexCom in a report on Tuesday, June 23rd. They issued a “buy” rating and a $86.00 target price for the company. Argus raised their target price on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Robert W. Baird set a $105.00 price target on DexCom in a report on Friday, July 31st. Finally, Truist Financial set a $93.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $88.71.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.